XBI241011C105000
- 0.04
- +0.01+33.33%
SPDR S&P Biotech ETF Newsroom
Gilead Upgraded to Overweight by Wells Fargo, PrEP Launch Cited
U.S. Supreme Court Declines To Review Rulings That Invalidate United Therapeutics' Patent; Decisions That Liquidia Does Not Infringe Any Valid Claims Of The Three Patents Originally Asserted By United Therapeutics Are Now Final And Not Subject To...
Liquidia Jumps as Court Rejects United Therapeutics Request for Appeal in Patent Dispute
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven by 'Strong AI Demand' And 'Margin Expansion'
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $75
Gilead Sciences Analyst Ratings
A Look Into United Therapeutics Inc's Price Over Earnings
Wells Fargo's 'Value Equity' Stocks: VZ, AZO, KR, and More
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Insmed Analyst Ratings
Comparing AbbVie With Industry Competitors In Biotechnology Industry
Behind the Scenes of AbbVie's Latest Options Trends
BridgeBio Granted Perform Rating at Oppenheimer on Market Challenges
U.S. Tweaks 2025 Medicare Price Negotiation Process
Dr. Reddy's Signs Voluntary Licensing Agreement With Gilead Sciences To Manufacture And Commercialise Lenacapavir In India And Other Countries
Gilead Signs Deals With Six Drugmakers for Generic Lenacapavir
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today